The Dutch Society of Medical Oncology has recommended second-line use of CDK4/6 inhibitors in patients with low-aggressive breast cancer, while awaiting the results of the Dutch SONIA trial on the preferred position of CDK4/6 inhibitor use [24, 44]. This evidence concerns the gene CDK4 and breast carcinoma.